康方生物-B(09926)坚守创新,行稳致远的肿瘤免疫新势力

国泰君安
18 Mar 2021

原标题:康方生物-B(09926)坚守创新,行稳致远的肿瘤免疫新势力 来源:国泰君安本报告导读:康方生物坚守自主创新,ACE平台和TETRABODY自有技术价值凸显,创新研发能力得到不断论证,在研管线丰富且进入兑现期。摘要:首次覆盖,给予“增持”评级。康方生物坚守自主创新,在研管线丰富,且管线品种具备内部combo的研发优势,2021年产品陆续进入商业化兑现期。我们预测2020-2022年收入分别...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10